Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

UBS
Deloitte
Johnson and Johnson
Baxter
Express Scripts
Fish and Richardson
Covington
Argus Health
Moodys
Mallinckrodt

Generated: August 23, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020943

« Back to Dashboard
NDA 020943 describes VERELAN PM, which is a drug marketed by Recro Gainesville and is included in one NDA. It is available from two suppliers. Additional details are available on the VERELAN PM profile page.

The generic ingredient in VERELAN PM is verapamil hydrochloride. There are sixteen drug master file entries for this compound. Thirty-eight suppliers are listed for this compound. Additional details are available on the verapamil hydrochloride profile page.

Summary for NDA: 020943

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:0
Therapeutic Class:Cardiovascular Agents
Formulation / Manufacturing:see details

Suppliers and Packaging for NDA: 020943

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 020943 NDA Kremers Urban Pharmaceuticals Inc. 62175-485 62175-485-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62175-485-37)
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL 020943 NDA Kremers Urban Pharmaceuticals Inc. 62175-486 62175-486-37 100 CAPSULE, EXTENDED RELEASE in 1 BOTTLE (62175-486-37)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength100MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength200MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Summary for product number 003

Active Rx/OTC/Discontinued:RXDosage:CAPSULE, EXTENDED RELEASE;ORALStrength300MG
Approval Date:Nov 25, 1998TE:ABRLD:Yes

Expired Orange Book Patents for NDA: 020943

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-001Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-003Nov 25, 1998► Subscribe► Subscribe
Recro Gainesville
VERELAN PM
verapamil hydrochloride
CAPSULE, EXTENDED RELEASE;ORAL020943-002Nov 25, 1998► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Federal Trade Commission
Citi
Express Scripts
Baxter
UBS
Fish and Richardson
US Department of Justice
US Army
Merck
Cipla

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot